When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of conversations with her husband, Javier. They were in

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or side effect disclosures. The

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super Bowl ad, leveling the accusation against brand-name weight loss drugs. Set to the tune of Childish Gambino’s “This Is America,

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating."

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

During the Super Bowl, Hims & Hers Health aired a commercial called “Sick of the System.” But before the 60-second spot was played on Fox Sunday night, the ad — which deems obesity “America’s deadliest epidemic,